Qpex Biopharma, Inc. clinical trials
Acquired by Shionogi, Jul 5, 2023 · source ↗
The registry lists 10 studies whose lead sponsor is Qpex Biopharma, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 25, 2026.
Before and after it joined Shionogi
- First submitted before Qpex Biopharma, Inc. became part of Shionogi
- 5
- First submitted after Qpex Biopharma, Inc. became part of Shionogi
- 5
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Qpex Biopharma, Inc.10 studies
Something wrong with this grouping? Tell us on the Shionogi page.
Studies
Recruiting first, then most recently updated. Showing 10 of 10. All Shionogi studies →
- A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal ImpairmentCompletedNCT07104162Phase 1
Sponsor listed in the registry: Qpex Biopharma, Inc. · First submitted after Qpex Biopharma, Inc. became part of Shionogi
- P1, DDI & MAD PK and Safety Study of Xeruborbactam Oral Prodrug in Combo With Ceftibuten in Healthy ParticipantsCompletedNCT06079775Phase 1
Sponsor listed in the registry: Qpex Biopharma, Inc. · First submitted after Qpex Biopharma, Inc. became part of Shionogi
- A DDI Study to Investigate PK and Safety of Cefiderocol in Combination With Xeruborbactam in Healthy Adult ParticipantsCompletedNCT06547554Phase 1
Sponsor listed in the registry: Qpex Biopharma, Inc. · First submitted after Qpex Biopharma, Inc. became part of Shionogi
- Mass Balance Study of [14C]Xeruborbactam (QPX7728) in Healthy Adult Male ParticipantsCompletedNCT07083817Phase 1
Sponsor listed in the registry: Qpex Biopharma, Inc. · First submitted after Qpex Biopharma, Inc. became part of Shionogi
- PK & Safety Study of Xeruborbactam Oral Prodrug Combined With Ceftibuten in Participants With Renal ImpairmentCompletedNCT06157242Phase 1
Sponsor listed in the registry: Qpex Biopharma, Inc. · First submitted after Qpex Biopharma, Inc. became part of Shionogi
- Phase 1 Study of Oral QPX2015 in Healthy Adult SubjectsCompletedNCT03939429Phase 1
Sponsor listed in the registry: Qpex Biopharma, Inc. · First submitted before Qpex Biopharma, Inc. became part of Shionogi
- Phase 1 Oral QPX7831 SAD and MAD in Healthy AdultsCompletedNCT04578873Phase 1
Sponsor listed in the registry: Qpex Biopharma, Inc. · First submitted before Qpex Biopharma, Inc. became part of Shionogi
- Drug-Drug Interaction Study of IV QPX2014 Combined With QPX7728 in Healthy Adult SubjectsCompletedNCT05072444Phase 1
Sponsor listed in the registry: Qpex Biopharma, Inc. · First submitted before Qpex Biopharma, Inc. became part of Shionogi
- SAD/MAD Safety and PK Study of QPX9003 (Novel Polymyxin) in Normal Healthy VolunteersCompletedNCT04808414Phase 1
Sponsor listed in the registry: Qpex Biopharma, Inc. · First submitted before Qpex Biopharma, Inc. became part of Shionogi
- P1 Single and Multiple Ascending Dose (SAD/MAD) Study of IV QPX7728 Alone and Combined With QPX2014 in NHVCompletedNCT04380207Phase 1
Sponsor listed in the registry: Qpex Biopharma, Inc. · First submitted before Qpex Biopharma, Inc. became part of Shionogi